Creo Medical Group (CREO) Share Price, News & Analysis

Company Overview

Creo Medical is a medical device company focused on the development and commercialisation of minimally invasive electrosurgical devices, bringing advanced energy to endoscopy. The Company's vision is to improve patient outcomes through the development and commercialisation of a suite of electrosurgical medical devices, each enabled by CROMA, powered by Kamaptive. The Group has developed the CROMA powered by Kamaptive full-spectrum adaptive technology to optimise surgical capability and patient outcomes. Kamaptive is a seamless, intuitive integration of multi-modal energy sources, optimised to dynamically adapt to patient tissue during procedures such as resection, dissection, coagulation and ablation of tissue. Kamaptive technology provides clinicians with increased flexibility, precision and controlled surgical solutions. CROMA currently delivers bipolar radiofrequency ("RF") energy for precise localised cutting and focused high frequency microwave ("MW") energy for controlled coagulation and ablation via a single accessory port. This technology, combined with the Group's range of patented electrosurgical devices, is designed to provide clinicians with flexible, accurate and controlled clinical solutions. The Directors believe the Company's technology can impact the landscape of surgery and endoscopy by providing a safer, less-invasive and more cost-efficient option for procedures. For more information, please refer to the website www.creomedical.com

Key Stats

• Today's Range: 13.03 to 13.50
• 50-Day Range: 13.06 to 14.63
• 52-Week Range: 9.52 to 18.50
• Volume: 279,668 shs
• Average Volume: 813,501 shs
• Market Capitalization: £64.61 million
• P/E Ratio: 13.30
• Dividend Yield: N/A
• Price Target: GBX 40
• Consensus Rating: N/A

Company Calendar

• Last Earnings: 5/22/2026
• Today: 8/03/2026

Industry, Sector and Symbol

• Stock Exchange: LON
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: LON:CREO
• CIK: N/A
• Web: creomedical.com
• Phone: +44-1291-606005
• Fax: N/A
• Employees: 279
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Creo Medical Group: GBX 40
• High Price Target: GBX 40
• Low Price Target: GBX 40
• Potential Upside/Downside: +200.8%
• Consensus Rating: N/A
• Rating Score (0-4): 0.00
• Research Coverage: 0 Analysts

Profitability

• EPS (Trailing Twelve Months): GBX 1
• Trailing P/E Ratio: 13.30
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -£25.04 million
• Net Margins: 88.33%
• Pretax Margin: N/A
• Return on Equity: 9.56%
• Return on Assets: -20.09%

Debt

• Debt-to-Equity Ratio: 8.20
• Current Ratio: 3.22
• Quick Ratio: 2.19

Sales & Book Value

• Annual Sales: £6 million
• Price / Sales: 10.77
• Cash Flow: GBX 5.47 per share
• Price / Cash Flow: 2.43
• Book Value: GBX 13.11 per share
• Price / Book: 1.01

Miscellaneous

• Outstanding Shares: 485,807,000
• Free Float: N/A
• Market Cap: £64.61 million
• Optionable: Not Optionable
• Beta: 1.62